全面的生物标志物检测是晚期非小细胞肺癌 (NSCLC) 最佳治疗的关键要求，在辅助治疗环境中具有新兴的相关性。为了推进确保肺癌诊断患者获得最佳治疗的目标，美国癌症协会国家肺癌圆桌会议 (ACS NLCRT) 于 2020 年 9 月举办了实践中优化肺癌生物标志物峰会，以协调合作伙伴实现确保全面肺癌治疗的目标对所有符合条件的 NSCLC 患者进行生物标志物检测。 ACS NLCRT 的《推进 NSCLC 综合生物标志物检测战略计划》是本次峰会的成果，其中包括促进对所有符合条件的患者进行综合生物标志物检测的行动。该方法是多方面的，包括政策层面的宣传以及开发和传播有针对性的教育材料、临床决策工具以及针对患者、医生和付款人的指南，旨在改善每个群体所经历的检测障碍。通俗语言摘要：ACS NLCRT 致力于改善肺癌患者的护理。 ACS NLCRT 支持全面的生物标志物测试，这对于确定所有符合条件的非小细胞肺癌患者的治疗方案至关重要。许多因素导致一些患者没有接受最佳的生物标志物检测。 ACS NLCRT 召开了一次合作峰会，并制定了一项战略计划，以实现和促进所有患者的全面生物标志物检测。这些计划包括开发教育材料和医生工具，以及倡导支持生物标志物测试的国家政策。© 2024 作者。 《癌症》由 Wiley periodicals LLC 代表美国癌症协会出版。

Comprehensive biomarker testing is a crucial requirement for the optimal treatment of advanced-stage non-small cell lung cancer (NSCLC), with emerging relevance in the adjuvant treatment setting. To advance its goal of ensuring optimal therapy for persons diagnosed with lung cancer, the American Cancer Society National Lung Cancer Roundtable (ACS NLCRT) held The Summit on Optimizing Lung Cancer Biomarkers in Practice in September 2020 to align its partners toward the goal of ensuring comprehensive biomarker testing for all eligible patients with NSCLC. The ACS NLCRT's Strategic Plan for Advancing Comprehensive Biomarker Testing in NSCLC, a product of the summit, comprises actions to promote comprehensive biomarker testing for all eligible patients. The approach is multifaceted, including policy-level advocacy and the development and dissemination of targeted educational materials, clinical decision tools, and guides to patients, physicians, and payers aimed at ameliorating barriers to testing experienced by each of these groups. PLAIN LANGUAGE SUMMARY: The ACS NLCRT works to improve care for patients with lung cancer. The ACS NLCRT supports comprehensive biomarker testing as essential to determine treatment options for all eligible patients with non-small cell lung cancer. Many factors lead to some patients not receiving optimal biomarker testing. The ACS NLCRT held a collaborative summit and developed a strategic plan to achieve and promote comprehensive biomarker testing for all patients. These plans include developing educational materials and physician tools and advocating for national policies in support of biomarker testing.© 2024 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.